Published in Arch Intern Med on August 15, 2006
Human Laboratory Study Of Varenicline in Smokers | NCT00709696
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ (2011) 6.19
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J (2007) 4.27
Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ (2012) 4.23
Tobacco addiction. Lancet (2008) 3.65
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ (2008) 3.63
Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ (2012) 3.09
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation (2013) 2.73
Varenicline for tobacco dependence. N Engl J Med (2008) 2.70
Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ (2015) 2.38
Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry (2008) 2.29
Smoking and suicide: a brief overview. Drug Alcohol Depend (2008) 2.08
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) (2007) 1.92
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health (2006) 1.91
Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry (2009) 1.91
Adapting smoking cessation treatment according to initial response to precessation nicotine patch. Am J Psychiatry (2013) 1.71
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review. Nicotine Tob Res (2010) 1.32
Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav (2008) 1.31
Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol (2009) 1.31
Behavioral counseling and varenicline treatment for smoking cessation. Am J Prev Med (2010) 1.27
Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med (2009) 1.19
Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence. Drug Alcohol Depend (2008) 1.19
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology (2011) 1.15
A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res (2011) 1.10
Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry (2009) 1.09
Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J (2009) 1.06
Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine Tob Res (2012) 1.05
Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs (2014) 1.04
A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities. Am J Addict (2010) 1.04
Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat (2008) 1.03
An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tob Control (2008) 1.01
Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat (2008) 1.01
Effect of fenfluramine on reinstatement of food seeking in female and male rats: implications for the predictive validity of the reinstatement model. Psychopharmacology (Berl) (2011) 0.98
Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Patient Care STDS (2011) 0.98
Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. J Dual Diagn (2012) 0.97
Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. Psychopharmacology (Berl) (2014) 0.95
Smoking, chronic wound healing, and implications for evidence-based practice. J Wound Ostomy Continence Nurs (2014) 0.95
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl) (2009) 0.92
Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend (2013) 0.91
Tobacco smoking cessation management: integrating varenicline in current practice. Vasc Health Risk Manag (2008) 0.90
Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat (2010) 0.89
Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology (Berl) (2010) 0.89
Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. Int J Environ Res Public Health (2009) 0.88
Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob Res (2012) 0.88
Resting-state functional connectivity and nicotine addiction: prospects for biomarker development. Ann N Y Acad Sci (2015) 0.88
Update on pharmacologic and nonpharmacologic therapies for smoking cessation. Can Fam Physician (2008) 0.87
Safety of varenicline among smokers enrolled in the lung HIV study. Nicotine Tob Res (2012) 0.87
New weapon to curb smoking: no more excuses to delay treatment. Arch Intern Med (2006) 0.86
Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend (2011) 0.86
Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients. Drug Healthc Patient Saf (2010) 0.86
Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther (2014) 0.86
Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. Am J Drug Alcohol Abuse (2014) 0.85
Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis. BMC Clin Pharmacol (2011) 0.85
Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology (Berl) (2008) 0.85
Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice. Psychopharmacology (Berl) (2014) 0.84
The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis (2008) 0.84
Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study. Neuropsychopharmacology (2012) 0.84
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence (2010) 0.84
The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study. Drug Alcohol Depend (2015) 0.84
Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.83
Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med (2014) 0.82
Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers. Nicotine Tob Res (2014) 0.82
Targeting nicotine addiction: the possibility of a therapeutic vaccine. Drug Des Devel Ther (2011) 0.82
Reward Anticipation Is Differentially Modulated by Varenicline and Nicotine in Smokers. Neuropsychopharmacology (2015) 0.82
The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. Psychopharmacology (Berl) (2012) 0.81
Gabapentin for smoking cessation. Nicotine Tob Res (2010) 0.81
Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. Nicotine Tob Res (2010) 0.81
Smoking cessation therapy with varenicline. Int J Chron Obstruct Pulmon Dis (2008) 0.81
Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial. Patient Prefer Adherence (2011) 0.81
Varenicline for smoking cessation: A review of the literature. Curr Ther Res Clin Exp (2009) 0.80
Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacology (2015) 0.80
[Varenicline - pharmacological therapy of tobacco dependence]. Wien Med Wochenschr (2009) 0.79
The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice. Pharmacol Biochem Behav (2011) 0.79
Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. J Dual Diagn (2007) 0.79
Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release. Eur J Pharmacol (2011) 0.79
Negative affective states and cognitive impairments in nicotine dependence. Neurosci Biobehav Rev (2015) 0.78
Organic cation transporter variation and response to smoking cessation therapies. Nicotine Tob Res (2014) 0.78
Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers. CNS Drugs (2015) 0.77
Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. Pharmacol Biochem Behav (2015) 0.77
Visual hallucinations associated with varenicline: a case report. J Med Case Rep (2009) 0.77
Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers. Ann Gen Psychiatry (2012) 0.77
Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers. Curr Addict Rep (2016) 0.77
Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc (2016) 0.77
An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. Am J Drug Alcohol Abuse (2014) 0.77
Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies. J Clin Pharm Ther (2014) 0.76
Varenicline and Risk of Self-Harm: A Nested Case-Control Study. PLoS One (2016) 0.75
Smoking cessation: an economic analysis and review of varenicline. Clinicoecon Outcomes Res (2009) 0.75
Paecilomycies japonica reduces repeated nicotine-induced neuronal and behavioral activation in rats. BMC Complement Altern Med (2015) 0.75
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.75
Partial agonism at nicotinic receptors with varenicline--a new approach to smoking cessation. Expert Opin Pharmacother (2006) 0.75
Partial nicotinic acetylcholine (alpha4beta2) agonists as promising new medications for smoking cessation. Indian J Pharmacol (2008) 0.75
Pharmacotherapy for smoking. Can Fam Physician (2011) 0.75
Progesterone and Postpartum Smoking Relapse: A Pilot Double-Blind Placebo-Controlled Randomized Trial. Nicotine Tob Res (2016) 0.75
Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo-controlled studies of varenicline. J Diabetes Investig (2016) 0.75
The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats. Behav Brain Res (2016) 0.75
Evaluation of the cardiovascular effects of varenicline in rats. Drug Des Devel Ther (2015) 0.75
Effects of short-term varenicline administration on cortisol in healthy, non-smoking adults: a randomized, double-blind, study. Psychopharmacology (Berl) (2013) 0.75
Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. Patient Prefer Adherence (2016) 0.75
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. Int J Chron Obstruct Pulmon Dis (2009) 0.75
Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study. Psychoneuroendocrinology (2017) 0.75
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006) 5.19
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med (2006) 3.30
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin (2007) 2.75
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol (2004) 2.50
A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther (2007) 2.06
Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry (2013) 2.06
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther (2005) 2.04
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax (2013) 1.99
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 1.78
Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. Am J Med (2004) 1.76
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72
Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. Am J Respir Crit Care Med (2010) 1.66
COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. COPD (2008) 1.65
A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction (2009) 1.60
Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav (2008) 1.52
Should troponin and creatinine kinase be routinely measured after vascular surgery? Vasc Med (2007) 1.44
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol (2007) 1.43
The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin (2008) 1.39
Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease. Respir Med (2004) 1.37
Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement (2010) 1.35
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc (2011) 1.28
Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res (2010) 1.26
Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med (2011) 1.26
Shotgun proteomic analysis of human-induced sputum. Proteomics (2006) 1.16
Smoking reduction in the Lung Health Study. Nicotine Tob Res (2004) 1.14
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med (2013) 1.12
Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax (2007) 1.12
Genetics of sputum gene expression in chronic obstructive pulmonary disease. PLoS One (2011) 1.11
The COPD Biomarker Qualification Consortium (CBQC). COPD (2013) 1.06
Factors associated with discussion of care plans and code status at the time of hospital admission: results from the Multicenter Hospitalist Study. J Hosp Med (2008) 1.04
The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin Ther (2002) 1.02
Inflammation in COPD: implications for management. Am J Med (2012) 1.00
Do hospitalists or physicians with greater inpatient HIV experience improve HIV care in the era of highly active antiretroviral therapy? Results from a multicenter trial of academic hospitalists. Clin Infect Dis (2008) 0.96
NF-kappaB mediates the survival of human bronchial epithelial cells exposed to cigarette smoke extract. Respir Res (2008) 0.96
Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 0.94
Diet and vitamin D as risk factors for lung impairment and COPD. Transl Res (2013) 0.94
Quality of care for decompensated heart failure: comparable performance between academic hospitalists and non-hospitalists. J Gen Intern Med (2008) 0.92
One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res (2008) 0.89
A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J Clin Psychopharmacol (2010) 0.88
One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD (2013) 0.88
The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res (2014) 0.88
A resident-led institutional patient safety and quality improvement process. Am J Med Qual (2012) 0.86
Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database. J Alzheimers Dis (2013) 0.86
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol (2013) 0.85
Varenicline: new treatment with efficacy in smoking cessation. Drugs Today (Barc) (2007) 0.85
Comparative testing of 5 nicotine systems: initial use and preferences. Am J Health Behav (2004) 0.85
Vitamin D, vitamin D binding protein, lung function and structure in COPD. Respir Med (2013) 0.84
Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav (2002) 0.84
Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study. Expert Opin Drug Deliv (2011) 0.83
Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. Drugs (2014) 0.82
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res (2014) 0.81
Using COPD multidimensional indices in routine clinical practice: DOSE meets all criteria. Prim Care Respir J (2012) 0.81
Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD. BMC Syst Biol (2014) 0.80
Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia. Schizophr Res (2011) 0.78
Code status discussions at hospital admission are not associated with patient and surrogate satisfaction with hospital care: results from the multicenter hospitalist study. Am J Hosp Palliat Care (2010) 0.78
Comparison of nicotine oral soluble film and nicotine lozenge on efficacy in relief of smoking cue-provoked acute craving after a single dose of treatment in low dependence smokers. Psychopharmacology (Berl) (2014) 0.77
Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder. Pharmacotherapy (2010) 0.77
Comment: Oral varenicline for smoking cessation. Ann Pharmacother (2007) 0.77
Response of vitamin D binding protein and free vitamin D concentrations to vitamin D supplementation in hospitalized premature infants. J Pediatr Endocrinol Metab (2015) 0.76
Bupropion SR for relapse prevention: a "slips-allowed" analysis. Am J Health Behav (2004) 0.76
Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell). BMC Clin Pharmacol (2007) 0.76
It's about time--directing our attention toward modifying the course of COPD. Respir Med (2008) 0.75
Isn't it time we talk? Advance care planning in South Carolina. J S C Med Assoc (2012) 0.75
Developing a successful hospitalist program. Physician Exec (2002) 0.75
Development of a primary-care tool to assess treatment success in COPD: consensus report from a closed meeting of respiratory and primary-care specialists. Prim Care Respir J (2004) 0.75
Comments on "Presidential address: advocacy as leadership". Am J Psychiatry (2007) 0.75